January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
2 citations
,
January 2026 in “Frontiers in Endocrinology” Next-generation Treg therapies could help achieve lasting immune tolerance in type 1 diabetes.
27 citations
,
March 2022 in “Forensic Toxicology” Micro-segmental hair analysis helps detect drug use patterns and estimate drug consumption days.
119 citations
,
March 2020 in “Frontiers in Bioengineering and Biotechnology” Asia has made significant progress in tissue engineering and regenerative medicine, but wider clinical use requires more development.